Community Practice Connections™: Cutting CVD Risk by Adding PCSK9 Inhibitors: What the Internist Needs to Know

Released On
May 31, 2019

Expires On
May 31, 2020

Media Type

Completion Time
90 minutes

Cardiology, Endocrinology

PCSK9 Inhibitors

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from Amgen.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This CME activity is primarily intended for internists, family physicians, nurse practitioners and physician assistants who treat patients with cardiovascular risk factors including hypercholesterolemia.

Program Overview

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab have been available since 2015, with growing evidence to support their role in patients with familial hypercholesterolemia and in those with or at high risk of cardiovascular disease (CVD). Although statins have been the mainstream of hypercholesterolemia treatment for over 30 years, PCSK9 inhibitors provide a more aggressive mechanism of action for lipid lowering when patients are not meeting lipid-lowering goals despite being on a maximally tolerated statin therapy with or without ezetimibe or when patients present with statin intolerance. The 2018 American College of Cardiology/American Heart Association multisociety guideline for cholesterol management in part recommends PCSK9 inhibitors as primary prevention for patients with very high-risk atherosclerotic cardiovascular disease (ASCVD) who are already on a high-intensity or maximal statin.

In this Community Practice Connections™ activity, 2 leading clinical lipidologists will provide insight into the latest evidence for PCSK9 inhibitors in the reduction of not only low-density lipoprotein cholesterol (LDL-C) but also non–high-density lipoprotein cholesterol and lipoprotein while maintaining a favorable safety and tolerability profile. Key points for incorporating PCSK9 inhibitors into clinical practice and tips to facilitate patient access will be included to readily broaden clinicians’ armamentarium of lipid-lowering treatments.

Benefits of Participation

  • Translate recent guidelines for cholesterol management into practice
  • Gain insight from expert lipidologists into adding nonstatin therapies when LDL-C goals are not met
  • Understand the implications of PCSK9 inhibitors for helping patients achieve absolute ASCVD risk reduction.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key recommendations of the current blood cholesterol management guidelines for ASCVD risk assessment and cholesterol management in patients with very high-risk ASCVD
  • Identify patient criteria for considering non-statin therapy(ies) for treatment of hyperlipidemia
  • Describe additional benefits observed in patients on PCSK9 inhibitors beyond reduction of LDL-C



Clinical Assistant Professor of Medicine
New York University Medical School and New York University Center for the Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY

Daniel Soffer, MD, FNLA, FACP

University of Pennsylvania Health System Internal Medicine/Clinical Lipidology
Preventive Cardiology
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest


  • Consultant: Akcea Therapeutics, Amgen
  • Speakers Bureau: Alexion, Amgen, Amarin Corporation, Sanofi, Regeneron
  • Grant/Research Support: Aegerion

Daniel Soffer, MD, FNLA, FACP

  • Consultant: Akcea Therapeutics, Amgen, Medicure, Regeneron
  • Speakers Bureau: Akcea Therapeutics (FCS disease state), Sanofi (FH disease state).

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members.

Method of Participation

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process